OM:HNSABiotechs
Hansa Biopharma (OM:HNSA) Heavy Net Loss Tests Bullish Revenue Growth Narrative
Hansa Biopharma (OM:HNSA) kicked off Q1 2026 with trailing 12 month revenue of SEK 222.3 million and a basic EPS loss of SEK 6.58, while the latest reported quarter in Q4 2025 showed revenue of SEK 76.0 million and a basic EPS loss of SEK 1.67. Over recent quarters, the company has seen quarterly revenue move between SEK 30.8 million and SEK 76.0 million, with basic EPS losses ranging from SEK 0.55 to SEK 2.53. Investors are weighing those headline trends against forecasts that point to...